-
Mashup Score: 8Novartis makes a $1B radiopharma deal, buying Mariana Oncology - 7 hour(s) ago
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B. The move, which could include another $750 million in milestones, further solidifies the Swiss drug giant’s embrace of the red-hot field of radiopharmaceuticals. Novartis
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 14
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna’s investigational individualized neoantigen therapy in combination with Merck’s Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma Advanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor event CAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2024. “As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are exercising financial discipline and have intensified our focus on building and
Source: investors.modernatx.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds. The Japanese biotech, which has a long list of drug development partners, will get
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 18
Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. The deal will see Ono acquire all outstanding Deciphera stock at a price of $25.60 per share, representing about a 75% premium over its Friday closing price of $14.65. It’s expected to
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning. Hudson also said that the French pharma is not expecting a significant impact from the US legislation targeting Chinese service providers given the
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0JPMorgan CEO Jamie Dimon Gives a Soft Landing Long Odds - 7 day(s) ago
Jamie Dimon says the U.S. consumer is in good shape right now, but a huge fiscal deficit and geopolitical challenges make him cautious about the future. The JPMorgan Chase CEO sits down with WSJ Editor in Chief Emma Tucker. Photo: Adam Falk
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 20
Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at boosting the company’s focus on high-impact projects. “We’ve taken out 20% of our molecules that have a lower likelihood to succeed, and we’ve added new ones through partnering,”
Source: endpts.comCategories: General Medicine News, General HCPsTweet
$NVS keeps racking up the (relatively small) radiopharma deals. $1B for a startup. From @ky_lahucik https://t.co/XUeeqeXU6a